MSD Biomarker Assays Selected for Resveratrol Study in Alzheimer’s Disease

Meso Scale Discovery, a division of Meso Scale Diagnostics, LLC. (MSD®), announced today that its assays for amyloid peptides and Tau have been selected for use in a clinical study in the field of neurodegeneration.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
Meso Scale Diagnostics, LLC. (MSD)

(PRWEB) May 23, 2014

The study, sponsored by the Alzheimer’s Disease Cooperative Study (ADCS), tests whether resveratrol, a compound found in red wine and red grapes, may be beneficial to patients suffering from mild to moderate dementia due to Alzheimer’s disease. Resveratrol has been shown to have multiple benefits for people with common illnesses associated with aging, but its role in Alzheimer’s disease requires further investigation.

“We have validated the MSD assays for use in our resveratrol trial for primary endpoint analyses as well as exploratory biomarker work with samples from this trial,” said Dr. Robert Rissman, Director of the ADCS Biomarker Core. Biomarkers in cerebral spinal fluid (CSF), such as amyloid peptides and Tau, are useful in characterizing the onset and progression of Alzheimer’s disease as well as determining whether treatments are effective.

“We are pleased to be part of this important study. Our investment in the development of these assays is a reflection of our commitment to advancing studies in neurodegenerative diseases,” said Jacob Wohlstadter, President and CEO of MSD.

MSD has been developing assays for neurodegeneration biomarkers for several years, but is now offering analytically validated assays to provide the Alzheimer’s research community next generation assays of greater precision and robustness than previously available. The assays have proven useful in support of clinical trials and longitudinal studies.

“We look forward to working with MSD on CSF biomarkers throughout the course of this study,” said Dr. Paul Aisen, Director of the ADCS. The resveratrol trial includes 26 U.S. academic institutions affiliated with the ADCS. It is supported by a grant from the National Institute on Aging.

About Meso Scale Diagnostics, LLC.
Meso Scale Diagnostics, LLC., based in Rockville, Maryland, develops, manufactures, and markets instruments and assays for array-based biological measurements for research use in life sciences and for biodefense applications. MSD is the world’s leading provider of highly sensitive multiplex immunoassays. More information about MSD and its products can be found at http://www.mesoscale.com.


Contact